CompletedNCT01923025
A PET Study With RO5545965 in Healthy Male Volunteers
Medication studyAges 25–50United KingdomSchizophrenia
Understand this study
Who was this study for?
Listed age limits: 25 years to 50 years.
- Listed locations
- LondonSee all locations and recruitment
- Study phase
- Phase 1Usually an early study focused on safety, tolerability, dosage, and side effects.
Study information
Study start dateAugust 2013
- Recruitment status
- Completed
- Enrollment listed in the registry
- 9
- Sponsor
- Hoffmann-La Roche
- Sponsor type
- Unknown or unclear
- Study type
- Drug
- Intervention type
- Medication / drug
- Study phase
- Phase 1Usually an early study focused on safety, tolerability, dosage, and side effects.
- Locations
- United Kingdom
- Age range
- From 25 Years to 50 Years
- Official registry ID
- NCT01923025
- Official title
Show the full official title
A Single Centre, Open Label Study to Characterize the PK-PDE10A Enzyme Occupancy Relationship of RO5545965 After a Single Dose in Healthy Male Volunteers Using [11C]IMA107 Positron Emission Tomography
Recruitment & locations
CompletedLondon
Questions about this study
Who is behind this study?
The study sponsor is Hoffmann-La Roche.
Did this study involve medication?
Yes. The study involved medication, including RO5545965.
Who was this study for?
Listed age limits: 25 years to 50 years.
Want to find a study that may fit you better?
Answer a few simple questions to explore HopeStage studies by condition, country, and situation.
Find a study that may fit meRelated studies
A 24-month, Prospective, Randomized, Active-Controlled, Open-Label, Rater Blinded, Multicenter, International Study of the Prevention of Relapse Comparing Long-Acting Injectable Paliperidone Palmit...
A 26-Week Extension Study of EVP-6124 (Alpha-7 nAChR) as an Adjunctive Pro-Cognitive Treatment in Schizophrenia Subjects on Chronic Stable Atypical Antipsychotic Therapy